Razvan Marculescu
About Razvan Marculescu
Razvan Marculescu is an Associate Scientist at Bristol Myers Squibb in the Greater Seattle Area, specializing in the development and qualification of molecular assays.
Current Role at Bristol Myers Squibb
Razvan Marculescu currently holds the position of Associate Scientist at Bristol Myers Squibb in the Greater Seattle Area. He has been with the company since September 2016. His work primarily involves the development and qualification of molecular assays. His expertise and dedication in this role have contributed to advancements in cell therapy and analytical development within the organization.
Previous Experience at Juno Therapeutics
Before joining Bristol Myers Squibb, Razvan Marculescu served as a Senior Research Associate at Juno Therapeutics, Inc. in Seattle, Washington. Although his tenure was brief in 2016, this position provided him with valuable experience that further honed his skills in the field of molecular assay development.
Education at Portland State University
Razvan Marculescu obtained his Bachelor’s Degree in Microbiology and Molecular Biology from Portland State University, where he studied from 2012 to 2015. He completed his Bachelor of Science (B.S.) in the same field, which provided a solid foundation for his career in scientific research and development.
Expertise in Molecular Assay Development
Razvan Marculescu specializes in the development and qualification of molecular assays, a critical area in scientific research and diagnostics. His work focuses on ensuring that molecular assays are precise, reliable, and effective for use in cell therapy and analytical development. This specialization has been a significant part of his roles at both Bristol Myers Squibb and Juno Therapeutics.
Interest in Cell Therapy and Analytical Development
Razvan Marculescu has a strong professional interest in cell therapy and analytical development. This focus is evident in his work at Bristol Myers Squibb, where he contributes to the research and development efforts aimed at advancing cell-based treatments and improving analytical methods. His passion for these fields drives his commitment to contributing to scientific progress.